Cell-free DNA versus circulating tumor DNA
In one sentence
Cell-free DNA is DNA outside intact cells in a sample; circulating tumor DNA is the portion that comes from tumor cells.
The intuition
Imagine collecting loose pages from many books. Most pages belong to ordinary books; a few may come from the book you want to track. Collecting more pages does not automatically reveal their origin.
Blood contains DNA fragments from several tissues. A test must establish which fragments, if any, are tumor-derived. The analogy stops at the idea of mixed origins: real DNA fragments can share sequence, and their sources require evidence.
How it works
Cell-free DNA (cfDNA) can be recovered from the plasma, the liquid fraction of blood after cells are separated. Circulating tumor DNA (ctDNA) is a subset of that material. It consists of fragments rather than whole circulating cancer cells. Cell turnover releases DNA, and clearance removes it; the measured amount reflects both processes and the sampling conditions.
A mutation can help identify origin when it is known from the tumor. Other methods use patterns such as DNA methylation, chemical marks on DNA, or fragment features. Each method has a particular target and validation. These approaches do not make all plasma DNA a cancer signal.
Blood cells can also acquire mutations as they age. This is called clonal hematopoiesis. A mutation in plasma may therefore come from a blood-cell lineage rather than the solid tumor. Matched blood-cell analysis or other assay-specific controls can help distinguish these sources.
The tumor-derived portion varies with disease biology, location, treatment and shedding. A tube may contain abundant cfDNA yet little or no detectable ctDNA. More background DNA is not proof of more cancer. A precise laboratory method cannot detect tumor fragments that never reached the collected sample.
Why it matters in cancer
- It separates a sample's total DNA yield from its tumor signal.
- It explains why a negative blood result can coexist with disease found in tissue or imaging.
- It prevents a newly detected mutation from being automatically labeled tumor evolution.
Common confusions
cfDNA versus ctDNA: the first names the material outside cells; the second names its tumor origin. They are not competing blood tests.
ctDNA versus circulating tumor cells: fragments and intact cells are different analytes. Their measurements cannot be substituted.
Amount versus origin: increased total cfDNA need not mean increased ctDNA. A mutation needs appropriate attribution.
Not detected versus absent: a negative result describes that sample under that assay's criteria. It does not count every cancer cell in the body.
How it is measured
An assay extracts cfDNA and tests for qualifying tumor features. Read its input, target scope, controls, units and result rule. The tumor-informed assay concept explains one design; units and detection limits explains the report.
Related concepts
- Variant allele fraction and cancer-cell fraction.
- Measurement, clinical association and useful decisions.
Sources and scope
Source check: October 9, 2026. General biology and assay interpretation; expert and learner review pending.
- NCI: circulating tumor DNA — fragment-based analyte and tumor origin.
- FDA 2024 guidance for curative-intent solid-tumor drug development — sampling, assay design and intended-use considerations.
- Razavi et al. 2019, high-intensity sequencing of plasma, white blood cells and tumor — primary evidence on non-tumor variant sources.